TORONTO, Canada (February 3, 2016) – PharmaCielo Ltd. today announced that its wholly owned subsidiary, Rionegro, Colombia based PharmaCielo Colombia Holdings S.A.S., has submitted its formal application to the Ministry of Health and the National Drugs Council to become a licensed grower and processor of medicinal-grade cannabis oil extracts, with plans to file an additional licence application for export in the near future.
This announcement comes after President Juan Manuel Santos signed regulatory Decree 2467, on December the 22nd, 2015, establishing a licensing framework for the cultivation, processing, research and development and exportation of cannabis derivatives for scientific and medical purposes.
“It is our goal to become the world’s leading supplier of naturally grown high-quality medicinal-grade cannabis oil extracts and there is no better location to do so than Colombia,” said Jon Ruiz, Director and CEO of PharmaCielo Ltd. “The country’s equatorial location and its plethora of ideal microclimates leave little doubt that Colombia will play a massive role in this rapidly developing international industry.”
Colombia is arguably the most economically advantageous country in the world when it comes to the production of large volumes of high-quality, low-cost cannabis based in large part on its expertise in the flower industry, knowledgeable and skilled labour force, environmental conditions and supportive government.
“The actions of the Government of Colombia demonstrate not only their bold commitment to the development of the Colombian economy, but also to the safety and well-being of the people of Colombia,” Mr. Ruiz stated. “We would very much like to be a part of this new economic sector and believe that with our business plan we will be a responsible partner for the government.”
The Ministry of Health and the National Drugs Council will be reviewing the applications for growing and processing licences. PharmaCielo Ltd. looks forward to the next steps, and anticipates having more announcements in the coming months.
About PharmaCielo Ltd.
PharmaCielo Ltd. is a global company privately held and headquartered in Canada, with a focus on processing and supplying all natural, medicinal-grade cannabis oil extracts and related products to large-channel distributors of standardized medical cannabis products.
The boards of directors and executive teams of PharmaCielo Ltd. and PharmaCielo Colombia are comprised of a diversely talented group of international business executives and specialists with the relevant expertise to ensure long-term success. The team recognized the significant role Colombia’s ideal location would play in building a sustainable business in the medical cannabis industry and has built a strong business plan focused on supplying the international medical marketplace.
PharmaCielo Colombia Holdings S.A.S., a wholly owned subsidiary of PharmaCielo Ltd., is headquartered at the company’s Nursery and Propagation Centre in Rionegro, Colombia.
This press release contains forward-looking statements. Often, but not always, forward-looking statements can be identified by the use of words such as “plans”, “expects” or “does not expect”, “is expected”, “estimates”, “intends”, “anticipates” or “does not anticipate”, or “believes”, or “recurring” or variations of such words and phrases or state that certain actions, events or results “may”, “could”, “would”, “might” or “will” be taken, occur or be achieved. Forward-looking statements involve known and unknown risks, uncertainties and other factors, such as demand for the Company’s products, currency exchange changes and risks, internal funding and the financial condition of the Company, product roll-out, competition, technological changes, and other commercial matters involving the Company, its products, and the markets in which the Company operates, as well as general economic conditions, which may cause the actual results, performance or achievements of the Company to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Actual results and developments are likely to differ, and may differ materially, from those expressed or implied by the forward-looking statements contained in this press release. There can be no assurance that forward-looking statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward-looking statements.
Except as required by law, we undertake no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise. However, any further disclosures made on related subjects in subsequent reports should be consulted.